Drugs / FAPI-46 GA-68

Trials 6

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT04457258 Sep 2020 → Dec 2026 expected sarcoma Jonsson Comprehensive Cancer Center Active not recruiting No outcome recorded
Phase 11 trial
Phase 1 NCT04459273 Aug 2020 → Jun 2025 overdue adrenal gland cancer, brain cancer, cancer of unknown primary site, cervical carcinoma +11 Jonsson Comprehensive Cancer Center Active not recruiting No outcome recorded
Phase 24 trials
Phase 2 NCT07549841 Sep 2026 → Oct 2027 expected — Nantes University Hospital Not yet recruiting No outcome recorded
Phase 2 NCT06540872 Feb 2026 → Mar 2028 expected ductal breast carcinoma in situ University of Münster Recruiting No outcome recorded
Phase 2 NCT07629609 Jan 2024 → Jan 2027 expected gastroesophageal cancer, malignant pancreatic neoplasm Barbara Malene Fischer Recruiting No outcome recorded
Phase 2 NCT05518903 Nov 2022 → Jun 2027 expected pancreatic ductal adenocarcinoma Mayo Clinic Recruiting No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as FAPI-46 GA-68 ChEMBL registry synonym — accepted as the source's own label CHEMBL5095334 ↗
Known as [68Ga]Ga-FAPI-46 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07549841 ↗
2

NCT07629609 ↗

NCT06540872 ↗

Known as Gallium Ga 68 FAPi-46 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04457258 ↗
2

NCT05518903 ↗

NCT04459273 ↗

Known as Gallium-68-fapi-46 ChEMBL registry synonym — accepted as the source's own label CHEMBL5095334 ↗
Modality Diagnostic / imaging agent “an imaging technique called 68Ga-FAPi-46 PET/CT” NCT04457258 ↗
Route Intravenous “Patients receive 68Ga-FAPi-46 intravenously (IV)” NCT04457258 ↗